Security National Bank of SO Dak purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,765 shares of the company’s stock, valued at approximately $538,000.
A number of other hedge funds also recently modified their holdings of TEVA. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $697,000. Macquarie Group Ltd. raised its stake in shares of Teva Pharmaceutical Industries Limited by 1.6% in the first quarter. Macquarie Group Ltd. now owns 935,126 shares of the company’s stock worth $30,008,000 after buying an additional 15,153 shares in the last quarter. Harbour Capital Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $380,000. Caxton Associates LP acquired a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth approximately $391,000. Finally, Sterling Investment Advisors Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 56.26% of the company’s stock.
Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 31.83 on Tuesday. The company has a market cap of $32.34 billion, a price-to-earnings ratio of 408.08 and a beta of 0.46. The stock has a 50 day moving average of $30.42 and a 200 day moving average of $32.94. Teva Pharmaceutical Industries Limited has a 52-week low of $27.59 and a 52-week high of $55.79.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.06. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The business had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $5.69 billion. During the same period last year, the company earned $1.20 EPS. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.76 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 4.27%. The ex-dividend date of this dividend was Thursday, June 1st. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently 5,802.90%.
TRADEMARK VIOLATION WARNING: “Security National Bank of SO Dak Takes Position in Teva Pharmaceutical Industries Limited (TEVA)” was published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thestockobserver.com/2017/07/18/security-national-bank-of-so-dak-buys-new-stake-in-teva-pharmaceutical-industries-limited-teva-updated-updated.html.
TEVA has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, April 17th. Deutsche Bank AG cut their price target on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, May 12th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $37.48 target price for the company in a research note on Tuesday, April 11th. Cowen and Company reissued an “outperform” rating and set a $50.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, April 4th. Finally, Citigroup Inc. lowered their target price on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, April 25th. Sixteen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $42.78.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.